Document is current
Any future updates will be listed below
-
Authors
Lim, Xin Yi https://orcid.org/0000-0002-2615-3166
Ram, Sanyogita https://orcid.org/0000-0002-5774-1972
Scahill, Shane https://orcid.org/0000-0001-5350-696X
Barnes, Joanne https://orcid.org/0000-0002-1522-8433
-
Funding
Funding for this research was provided by:
Auckland Medical Research Foundation (1224004)
University of Auckland
- License Information
-
More Information
Article History
Received: 16 November 2025
Accepted: 24 March 2026
First Online: 28 April 2026
Declarations
:
: XYL is a doctoral candidate studying the contributions of the natural health products (NHPs) industry to pharmacovigilance for NHPs. SR and SS have no conflicts of interest to declare. In the last 3 years, JB has received: royalties from Elsevier and SpringerNature in respect of authorship of reference texts on herbal medicines; travel expenses and/or conference expenses from United States Pharmacopeia, UK Drug Safety Research Unit, University of Mississippi (USA), Southern Cross University (Australia), International Society of Pharmacovigilance, and South African Botanical Products Association in respect of invited meetings/conference presentations; non-financial support (clinical trial supplies) from Achieve Life Sciences and NZVAPOR (both 2022-24) as a co-investigator. JB is an Editorial Board member of Drug Safety. JB was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.
: This is a scoping review. No ethical approval is required.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
: Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.
